Company intelligence / Profile preview
Hugel
Chuncheon-si, Gangwon-do*, South Koreahugel-inc.com ↗
- Ownership
- Public · 145020
- Development stage
- Commercial
01
Overview
Hugel has established itself as a global leader in medical aesthetics since its founding in South Korea in 2001. Its flagship product line includes botulinum toxin injectables—marketed under various names such as Botulax domestically and Letybo internationally—which have received regulatory approval across the US, China, Europe, Australia, Canada, and more. The company also markets hyaluronic acid fillers ("The Chaeum", "Dermalax"), absorbable sutures ("BlueRose"), threads for lifting procedures, skin boosters/cosmetics ("Wellage"), and related devices. Clinical results from phase III studies support efficacy/safety of letibotulinumtoxinA for glabellar lines; the company aims to capture significant market share globally.[2][4][5]
- Therapeutic areas
- NeurologyDermatology
- Modalities
- Biologic (botulinum toxin)Protein (botulinum toxin)Hyaluronic acid fillerSmall molecule (cosmetics/derma products)Device (absorbable sutures/threads)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Joint venture with Croma Pharma GmbH formed "Hugel Aesthetics" to expand into North America/Oceania markets [8]distribution partners worldwide.
04
Financials
- Market cap
- $1.5B
- Total revenue
- $314M
- Enterprise value
- $1.1B
Beyond the preview
Go deeper on Hugel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hugel.